Clinical trial
Relapse Prevention, RoW: Study to Evaluate Prevention of Relapse in Patients in…
NCT00228462 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00228462 |
|---|---|
| Title | Relapse Prevention, RoW: Study to Evaluate Prevention of Relapse in Patients in Stable Chronic Schizophrenia Receiving Either Seroquel or Placebo |
| Official title | A 1-year, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Phase 3 Study to Evaluate Prevention of Relapse in Patients in Stable Chronic Schizophrenia Receiving Either Sustained-release Quetiapine Fumarate (SEROQUEL) or Placebo (Abbreviated) |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Seroquel (quetiapine) |
| Enrollment | 197 |
| Start date | Mar 1, 2005 |
| Completion | Apr 1, 2006 |
| First posted | Sep 29, 2005 |
| Last update posted | Jan 4, 2013 |
| Countries | Bulgaria, Poland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: